Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.

The company’s experimental daily pill helped patients lose an average 16.6% of their weight, according to late-stage trial, ...

Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The ...

The number of people who reported experiencing constant thoughts about food declined by 46% after starting treatment with ...

Novo Nordisk's Wegovy will soon come in a pill form that's as effective as with a needle. A new study shows Wegovy taken once ...

Novo Nordisk (NVO) said Wednesday that oral semaglutide 25 mg (Wegovy in a pill) delivered 16.6% weight loss in people with ...

Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVO’s stock dip ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...

CNBC's Angelica Peebles reports on Novo Nordisk shares surging after the company announced that its Wegovy pill trial showed ‘significant’ weight reduction.

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option ...

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study ...